clinical trial · NCT05814757
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
Dry Eye SyndromesEye DiseasesOTX-DEDControlled InsertionCollagen Punctal Plug
brief summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
started
May 11, 2023
primary completion
May 22, 2024
completion
May 22, 2024
last updated
Jul 10, 2024
detailed description
Randomized, double-masked, study to evaluate the efficacy and safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the symptoms of dry eye disease (DED). The subjects will be followed for approximately two months.
official title
A Randomized, Double-masked, Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol